Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06494397 | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions | PHASE1 | COMPLETED | 26 | — | — | Jul 11, 2024 | Oct 24, 2024 | Sep 19, 2025 | 3 | United States |
As measured by plasma concentrations
| Arm | Type | Description |
|---|---|---|
| Sequence A: VHX-896 then iloperidone | EXPERIMENTAL | - |
| Sequence B: Iloperidone then VHX-896 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VHX-896 and iloperidone | DRUG | oral tablet |
| Iloperidone and VHX-896 | DRUG | oral tablet |
Inclusion Criteria: * Male or female patients 18 to 65 years of age (inclusive) * Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type, according to the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision (DSM-5-TR) * Patients must be symptom...